Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APLT Applied Therapeutics	$0.46 -1.7%	$0.39	$0.30 ▼ $10.62	$66.53M	1.82	3.47 million shs	1.06 million shs
BCEL Atreca	$0.09	$0.09	$0.05 ▼ $1.20	$3.57M	1.03	4.61 million shs	N/A
FHTX Foghorn Therapeutics	$6.13 +0.5%	$4.67	$2.94 ▼ $10.25	$340.02M	3.05	143,427 shs	148,403 shs
INZY Inozyme Pharma	$4.00	$3.76	$0.72 ▼ $6.24	$258.25M	2.27	950,321 shs	N/A
SELB Selecta Biosciences		$1.06	$0.81 ▼ $1.99	$136.76M	0.84	979,585 shs	2.77 million shs

7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APLT Applied Therapeutics	+7.36%	+13.48%	+36.20%	+41.11%	-91.71%
BCEL Atreca	0.00%	0.00%	0.00%	0.00%	0.00%
FHTX Foghorn Therapeutics	+3.74%	+12.96%	+27.35%	+60.53%	-4.24%
INZY Inozyme Pharma	0.00%	0.00%	+0.50%	+335.02%	-30.31%
SELB Selecta Biosciences	0.00%	0.00%	0.00%	0.00%	0.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
APLT Applied Therapeutics	4.5429 of 5 stars	3.3	3.0	0.0	4.7	3.8	1.7	1.3
BCEL Atreca	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
FHTX Foghorn Therapeutics	2.1144 of 5 stars	3.6	0.0	0.0	0.0	3.3	1.7	0.6
INZY Inozyme Pharma	3.5236 of 5 stars	4.2	4.0	0.0	0.0	2.7	2.5	0.0
SELB Selecta Biosciences	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APLT Applied Therapeutics	2.50	Moderate Buy	$6.10	1,220.63% Upside
BCEL Atreca	0.00	N/A	N/A	N/A
FHTX Foghorn Therapeutics	3.13	Buy	$12.13	97.80% Upside
INZY Inozyme Pharma	2.44	Hold	$11.75	193.75% Upside
SELB Selecta Biosciences	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest BCEL, INZY, APLT, SELB, and FHTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/16/2025	INZY Inozyme Pharma	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/16/2025	INZY Inozyme Pharma	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/16/2025	INZY Inozyme Pharma	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Moderate Buy ➝ Hold
5/16/2025	INZY Inozyme Pharma	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Equal Weight	$4.00
5/16/2025	INZY Inozyme Pharma	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold	$15.00 ➝ $4.00
5/15/2025	FHTX Foghorn Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$9.00 ➝ $9.00
5/14/2025	APLT Applied Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Sector Perform ➝ Sector Perform	$1.50 ➝ $1.50
5/14/2025	FHTX Foghorn Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/14/2025	INZY Inozyme Pharma	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$15.00 ➝ $12.00
4/30/2025	FHTX Foghorn Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$9.00 ➝ $9.00
4/30/2025	FHTX Foghorn Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00 ➝ $13.00

(Data available from 7/18/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APLT Applied Therapeutics	$460K	142.16	N/A	N/A	$0.49 per share	0.94
BCEL Atreca	N/A	N/A	N/A	N/A	$2.01 per share	N/A
FHTX Foghorn Therapeutics	$22.60M	15.12	N/A	N/A	($0.82) per share	-7.48
INZY Inozyme Pharma	N/A	N/A	N/A	N/A	$0.90 per share	N/A
SELB Selecta Biosciences	$110.78M	0.00	N/A	9.91	$0.61 per share	0.00

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APLT Applied Therapeutics	-$105.62M	-$0.43	0.00	N/A	N/A	N/A	-184.67%	-84.02%	8/6/2025 (Estimated)
BCEL Atreca	-$97.16M	-$2.50	N/A	N/A	N/A	N/A	-157.90%	-71.39%	N/A
FHTX Foghorn Therapeutics	-$86.62M	-$1.36	0.00	N/A	N/A	-342.23%	N/A	-27.28%	8/6/2025 (Estimated)
INZY Inozyme Pharma	-$102.02M	-$1.69	N/A	N/A	N/A	N/A	-159.93%	-82.48%	8/5/2025 (Estimated)
SELB Selecta Biosciences	$35.38M	-$0.22	N/A	N/A	N/A	-72.04%	-44.13%	-22.00%	N/A

Latest BCEL, INZY, APLT, SELB, and FHTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q2 2025	FHTX Foghorn Therapeutics	-$0.32	N/A	N/A	N/A	N/A	N/A
8/6/2025	Q2 2025	APLT Applied Therapeutics	-$0.17	N/A	N/A	N/A	$0.42 million	N/A
8/5/2025	Q2 2025	INZY Inozyme Pharma	-$0.36	N/A	N/A	N/A	N/A	N/A
5/14/2025	Q1 2025	FHTX Foghorn Therapeutics	-$0.30	-$0.30	N/A	-$0.30	$4.96 million	$5.95 million
5/14/2025	Q1 2025	INZY Inozyme Pharma	-$0.43	-$0.44	-$0.01	-$0.44	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
APLT Applied Therapeutics	N/A	N/A	N/A	N/A	N/A
BCEL Atreca	N/A	N/A	N/A	N/A	N/A
FHTX Foghorn Therapeutics	N/A	N/A	N/A	N/A	N/A
INZY Inozyme Pharma	N/A	N/A	N/A	N/A	N/A
SELB Selecta Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APLT Applied Therapeutics	N/A	3.00	3.00
BCEL Atreca	N/A	1.58	1.58
FHTX Foghorn Therapeutics	N/A	3.16	3.16
INZY Inozyme Pharma	0.65	2.19	2.19
SELB Selecta Biosciences	0.21	4.18	4.18

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
APLT Applied Therapeutics	98.31%
BCEL Atreca	37.47%
FHTX Foghorn Therapeutics	61.55%
INZY Inozyme Pharma	88.30%
SELB Selecta Biosciences	41.95%

Insider Ownership

Company	Insider Ownership
APLT Applied Therapeutics	1.60%
BCEL Atreca	11.30%
FHTX Foghorn Therapeutics	7.58%
INZY Inozyme Pharma	12.18%
SELB Selecta Biosciences	31.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
APLT Applied Therapeutics	30	141.58 million	139.31 million	Optionable
BCEL Atreca	130	39.62 million	35.15 million	Optionable
FHTX Foghorn Therapeutics	120	55.74 million	51.52 million	Optionable
INZY Inozyme Pharma	50	64.56 million	56.70 million	Optionable
SELB Selecta Biosciences	64	155.20 million	106.78 million	Optionable

BCEL, INZY, APLT, SELB, and FHTX Headlines

Recent News About These Companies

2025 Poinsettias catalog available from Selecta One

January 31, 2025 | nurserymag.comN

2025 Poinsettias catalog available now from Selecta One

January 29, 2025 | greenhousemag.comG

Leigh Francis insists Bo Selecta! reboot will never happen

October 20, 2024 | msn.com

LISTEN: Firebeatz and Noise Cans Join Forces in “Selecta”

September 25, 2024 | runthetrap.comR

Leigh Francis in Leeds: Keith Lemon and Bo Selecta! star announces evening of laughter at Leeds Grand Theatre

September 23, 2024 | msn.com

Leigh Francis interview: Leeds comedian of Keith Lemon and Bo' Selecta! fame on his fear of being cancelled

September 20, 2024 | msn.com

Astellas licenses companion drug for Pompe gene therapy

September 8, 2024 | pharmaphorum.comP

Craig David spoke out on how Bo Selecta 'ruined his life'

May 15, 2024 | ladbible.comL

Craig David says Bo Selecta ‘ruined his life’

May 14, 2024 | joe.co.ukJ

Leigh Francis says Bo Selecta couldn’t be made today because ‘you’ve got to be mindful nowadays’

May 12, 2024 | joe.co.ukJ

Craig David says Leigh Francis' Bo Selecta! skit 'sent him down a dark road'

May 6, 2024 | msn.com

Selecta Biosciences files patent for enhanced gene therapy using viral vectors and immunosuppressants

March 12, 2024 | pharmaceutical-technology.comP

Selb, Germany - Weather Forecasts | Maps | News - Yahoo Weather

January 23, 2024 | yahoo.com

Nanotechnology in Massachusetts – companies, research, and degree programs

January 13, 2024 | nanowerk.comN

Cartesian Therapeutics Inc (RNAC)

December 15, 2023 | investing.com

Selecta Biosciences, Cartesian Therapeutics Merge to Create Public RNA Cell Therapy Firm

November 14, 2023 | precisionmedicineonline.comP

Further weakness as Selecta Biosciences (NASDAQ:SELB) drops 17% this week, taking five-year losses to 85%

November 14, 2023 | finance.yahoo.com

Pared-down Selecta merges with Maryland biotech

November 13, 2023 | bizjournals.com

Selecta Biosciences Merges With Cartesian To Focus On Autoimmune Cell Therapy

November 13, 2023 | msn.com

Selecta Biosciences Merges With Cartesian Therapeutics In All-stock Deal

November 13, 2023 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

BCEL, INZY, APLT, SELB, and FHTX Company Descriptions

Applied Therapeutics NASDAQ:APLT

$0.46 -0.01 (-1.70%)

Closing price 04:00 PM Eastern

Extended Trading

$0.46 0.00 (-0.63%)

As of 07:48 PM Eastern

Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG. It also develops AT-001 (also called caficrestat) that is in phase 3 clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy. The company has exclusive license and supply agreement with Mercury Pharma Group Limited to commercialize drug products containing AT-007. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.

Atreca NASDAQ:BCEL

Atreca, Inc., a clinical-stage biopharmaceutical company, discovers and develops antibody-based immunotherapeutics to treat a range of solid tumor types. Its lead product candidate is ATRC-101, a monoclonal antibody with a novel mechanism of action and target derived from an antibody identified using its discovery platform. The company's ATRC-101 product candidate reacts in vitro with a majority of human ovarian, non-small cell lung, colorectal, and breast cancer samples from multiple patients; and ATRC-501/MAM01, that targets the circumsporozoite protein of Plasmodium falciparum for the treatment of malaria. Its products in pre-clinical stage include APN-497444, an antibody drug conjugate (ADC) against a novel tumor glycan target; and APN-346958, a CD3 bispecific T-cell engager against an RNA-binding protein target. It has a collaboration and license agreement with Xencor, Inc. for research, development, and commercialization of novel CD3 bispecific antibodies in oncology; licensing agreement with the Bill & Melinda Gates Medical Research Institute for the development and commercialization of MAM01/ATRC-501 for the prevention of malaria. The company was incorporated in 2010 and is based in San Carlos, California.

Foghorn Therapeutics NASDAQ:FHTX

$6.13 +0.03 (+0.49%)

Closing price 04:00 PM Eastern

Extended Trading

$6.14 +0.01 (+0.16%)

As of 04:04 PM Eastern

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It develops FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM that is in phase I for the treatment of relapsed and/or refractory acute myeloid leukemia/myelodysplastic syndrome. The company is also developing therapies for mutant cancers, such as Non-Small Cell Lung, bladder, endometrial, colorectal, and melanoma cancers; and dependent cancers, including prostate cancer and diffuse large b-cell lymphoma. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Inozyme Pharma NASDAQ:INZY

$4.00 0.00 (0.00%)

As of 07/1/2025

Inozyme Pharma, Inc., a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

Selecta Biosciences NASDAQ:SELB

Selecta Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. The company's lead therapeutic gene therapy program is SEL-302 that is in Phase I clinical trial to enhance the treatment of methylmalonic acidemia. It is also developing biologic therapies, such as SEL-212 that is in Phase III clinical trials for the treatment of chronic refractory gout; and product candidates to treat IgA-mediated diseases, including IgA nephropathy, linear IgA bullous dermatitis, IgA pemphigus, and Henoch-Schonlein purpura. In addition, the company is developing gene therapies comprising for the treatment of pompe disease, duchenne muscular dystrophy, limb-girdle muscular dystrophy, lysosomal storage disorder, and other autoimmune diseases. Further, it develops tolerogenic therapies to treat autoimmune diseases. The company has license and collaboration agreements with Ginkgo Bioworks Holdings, Inc.; Genovis AB (publ.); Cyrus Biotechnology, Inc.; IGAN Biosciences, Inc.; Astellas Therapeutics, Inc.; Takeda Pharmaceuticals USA, Inc.; Swedish Orphan Biovitrum AB (publ.); Sarepta Therapeutics, Inc.; Asklepios Biopharmaceutical, Inc.; Massachusetts Institute of Technology; and Shenyang Sunshine Pharmaceutical Co., Ltd. Selecta Biosciences, Inc. was incorporated in 2007 and is headquartered in Watertown, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time